• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

    40.42 +0.16 (+0.41%)
    Streaming Delayed Price Updated: 1:18 PM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 908,772
    Open 40.55
    Bid (Size) 40.42 (700)
    Ask (Size) 40.43 (300)
    Prev. Close 40.26
    Today's Range 40.34 - 40.98
    52wk Range 25.77 - 41.70
    Shares Outstanding 388,132,400
    Dividend Yield 2.18%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Royalty Pharma Announces Dividend Increase
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)
    The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property

    Performance

    YTD
    +4.0%
    +4.0%
    1 Month
    +6.1%
    +6.1%
    3 Month
    +11.9%
    +11.9%
    6 Month
    +11.9%
    +11.9%
    1 Year
    +54.3%
    +54.3%

    More News

    Read More
    News headline image
    3 Overrated Stocks We Steer Clear Of
    Via StockStory
    News headline image
    Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    3 Healthcare Stocks We’re Skeptical Of
    Via StockStory
    Topics Stocks
    News headline image
    Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗
    Via Chartmill
    News headline image
    Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    3 Mid-Cap Stocks That Concern Us
    Via StockStory
    News headline image
    Royalty Pharma to Present at Upcoming Investor Conferences
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
    Via Investor's Business Daily
    News headline image
    3 Value Stocks with Warning Signs
    Via StockStory
    Topics Supply Chain
    News headline image
    3 Low-Volatility Stocks We Find Risky
    Via StockStory
    News headline image
    Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?
    Via StockStory
    Topics Stocks Supply Chain
    News headline image
    Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗
    Via Benzinga
    Topics Economy
    News headline image
    Royalty Pharma Reports Third Quarter 2025 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗
    Via Chartmill

    Frequently Asked Questions

    Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
    Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
    What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
    Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
    The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
    What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
    The current price of Royalty Pharma plc - Class A Ordinary Shares is 40.42
    When was Royalty Pharma plc - Class A Ordinary Shares last traded?
    The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 01/09/26 01:18 PM ET
    What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
    The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 15.69B
    How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
    Royalty Pharma plc - Class A Ordinary Shares has 16B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.